CN115381954A - Combined medicine for treating osteosarcoma - Google Patents
Combined medicine for treating osteosarcoma Download PDFInfo
- Publication number
- CN115381954A CN115381954A CN202110560718.6A CN202110560718A CN115381954A CN 115381954 A CN115381954 A CN 115381954A CN 202110560718 A CN202110560718 A CN 202110560718A CN 115381954 A CN115381954 A CN 115381954A
- Authority
- CN
- China
- Prior art keywords
- combination
- osteosarcoma
- use according
- medicament
- pde4 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008968 osteosarcoma Diseases 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 35
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229960002328 chloroquine phosphate Drugs 0.000 claims abstract description 60
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 29
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 6
- 229960002586 roflumilast Drugs 0.000 claims description 6
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 6
- 229950005741 rolipram Drugs 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 claims description 2
- 229950001653 cilomilast Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 201000003434 periosteal osteogenic sarcoma Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 201000008864 small cell osteogenic sarcoma Diseases 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 claims 1
- 229950008499 plitidepsin Drugs 0.000 claims 1
- 108010049948 plitidepsin Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 47
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 230000004900 autophagic degradation Effects 0.000 description 7
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical class ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 7
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 229960003677 chloroquine Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 2
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 2
- 229960001164 apremilast Drugs 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012822 autophagy inhibitor Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a combination medicament for the treatment of malignant tumours, in particular osteosarcoma, which comprises the PDE4 inhibitor ZL-n-91 and chloroquine phosphate. The combined medicine can effectively treat osteosarcoma, has the effect obviously superior to that of a PDE4 inhibitor ZL-n-91 and chloroquine phosphate which are used independently, shows that the two have obvious synergistic effect after being used in a matched mode, has strong anti-tumor activity and small side effect, and provides a new treatment option for patients who lose clinical operation indications, cannot perform operations and have poor radiotherapy and chemotherapy effects.
Description
Technical Field
The application belongs to the field of antitumor drugs, and particularly provides a combined drug for treating osteosarcoma, which contains a PDE4 inhibitor ZL-n-91 and chloroquine phosphate.
Background
Osteosarcoma (OS) is one of the most common malignant bone tumors, defined by the World Health Organization (WHO) as a primary malignant bone tumor consisting of mesenchymal cells producing osteoid and immature bone. Osteosarcoma often occurs in active growth sites, such as the lower femur, the upper tibia, the upper humerus, etc., and its clinical manifestations include: bone or joint pain, localized swelling, lameness. When the disease condition further worsens to the general state, it manifests as fever, malaise, weight loss, anemia and failure. In most countries, the age-normalized ratio (ASR) of osteosarcoma is 0.20-0.35/10 ten thousand, accounting for 20-40% of bone tumors, wherein in china it accounts for 20%. Osteosarcoma occurs in adolescents at a high rate in men compared to women, and the overall survival rate of patients with osteosarcoma has changed little, approximately 70%, over the last thirty years. But for patients with metastatic disease and those who do not respond well to initial therapy, 5-year survival rates are only 25% in people between 2 and 68 years of age. Therefore, the search for new molecular targets is of great significance for the early diagnosis and targeted therapy of osteosarcoma patients. The current treatment modes of osteosarcoma are new auxiliary chemotherapy before operation, surgical resection and auxiliary chemotherapy after operation. Chemotherapy drugs include Methotrexate (MTX), adriamycin (ADM), cisplatin (DDP), and Ifosfamide (IFO), but high doses of chemotherapy drugs cause significant side effects, and can cause rare toxic effects such as cardiotoxicity, acute and chronic nephrotoxicity, neurotoxicity, hearing loss, and infertility, in addition to common complications such as alopecia, myelosuppression, mucositis, nausea, and vomiting. Therefore, further research is necessary to identify effective drugs and develop new therapeutic strategies with less side effects to treat this fatal disease.
Research shows that the phosphodiesterase 4 inhibitor (PDE 4 i) Roflumilast (Roflumilast) can obviously inhibit the growth of ovarian cancer, lung cancer and B cell lymphoma; in another study, PDE4i Rolipram (Rolipram) was found to inhibit proliferation of the human mandibular OS cell line HOSM-1, suggesting that PDE4i has potential anti-OS effects. Rolipram is the first prototype PDE4 inhibitor but fails to market first due to its severe adverse effects and is commonly used as a positive control in subsequent studies of PDE4 inhibitors. In addition to Rolipram, researchers have further developed a new generation of PDE4 inhibitors, of which Roflumilast, apremilast, and Crisborole were continuously approved for marketing. Oral Roflumilast was approved in the european union and us in 2010 and 2011 for the treatment of severe COPD and asthma symptoms, apremilast was approved in the us (2014) for active psoriatic arthritis patients and moderate to severe plaque psoriasis patients, and crisabarole was approved in the us (2016) for topical treatment of mild to moderate atopic dermatitis in patients 2 years and older. However, the PDE4 inhibitors have a narrow therapeutic window and are associated with side effects such as nausea and vomiting during treatment. Several novel PDE4 selective inhibitors have been developed for the above side effects, such as ZL-n-91, developed by Kyohimu, university of North Carolina:
ZL-n-91 is a novel selective PDE4i, which is several thousand times more selective than other PDE family molecules. The 2008 Ruihong Ma research shows that ZL-n-91 has an inhibition effect on IL-17production by memory T helper (Th) 17 cells, and has no influence on cell viability. A2010 study by Hui-Fang Tang et al found ZL-n-91 to improve the smoking (CS) -induced inflammatory response in a COPD-like model in male Sprague-Dawley rats, and the authors further found ZL-n-91 to be useful in the treatment of lipopolysaccharide-induced Acute Lung Injury (ALI) in mice. In addition, the study finds that ZL-n-91 can inhibit the proliferation of prostate cancer cell PC-3, but no actual study verification exists for the curative effect of other cancers.
Chloroquine phosphate, chloroquine diphosphate salt, CAS number 50-63-5, structural formula:
the chloroquine is a classical antimalarial drug, and researches in recent years show that the chloroquine has antitumor activity and has various action mechanisms on tumors, such as tumor cell apoptosis induction, autophagy inhibition and the like. The chloroquine phosphate serving as a weakly alkaline medicine can selectively enter acidic lysosomes of tumor cells, effectively inhibit the acidic lysosomes of the tumor cells to inhibit autophagy and the paradoxical reaction p The action of H normal cells is weak, which lays a good microenvironment foundation for chloroquine to better act on tumor cells and reduce adverse reactions of normal tissues. Research shows that autophagy can reduce the sensitivity of chemotherapeutic drugs by regulating energy metabolism in a stress environment and promote the survival of tumor cells. The autophagy inhibitor chloroquine can effectively prevent autophagy in the process of tumor toxicity chemotherapy, and the blocking of autophagy can promote tumor cells to die and increase the sensitivity of the tumor cells to chemotherapeutic drugs. Thus, targeted drugs and regulated autophagy bidirectional interventions could be an effective cancer treatment strategy.
Disclosure of Invention
The invention aims to provide a combined medicine for treating osteosarcoma, which solves the problem that the medicine effect is influenced due to the fact that the body is intolerant caused by the fact that the PDE4 inhibitor ZL-n-91 is singly used for treating high concentration. The invention uses in vitro tumor cell culture, and researches the combined effect of ZL-n-91 and chloroquine through cell proliferation experiments, plate clone formation experiments and apoptosis experiments. The experiment proves that: chloroquine phosphate (CQ) has synergistic effect on ZL-n-91 in inhibiting proliferation of MNNG/HOS, U2OS and Saos-2 in osteosarcoma cells, and can enhance the apoptosis promoting effect mediated by ZL-n-91.
In one aspect, the present application provides a combination comprising a PDE4 inhibitor and chloroquine phosphate for the treatment of a malignant tumor.
In another aspect, the application provides the use of a PDE4 inhibitor and chloroquine phosphate in the manufacture of a combination for the treatment of a malignant tumor.
Further, the malignant tumor is osteosarcoma.
Further, the PDE4 inhibitor is ZL-n-91.
Further, the drug inhibits tumor cell proliferation.
Further, the drug induces apoptosis of tumor cells.
Further, the molar ratio of the PDE4 inhibitor to the chloroquine phosphate in the medicament is 40.
Further, the molar ratio of the PDE4 inhibitor to the chloroquine phosphate in the medicament is 20.
Further, the molar ratio of the PDE4 inhibitor to chloroquine phosphate in the medicament is 10.
Further, the PDE4 inhibitor and the chloroquine phosphate in the medicament are administered simultaneously or separately.
Further, the medicine is in an injection form.
The chloroquine phosphate described in the present application may be used interchangeably with chloroquine, chloroquine phosphate, etc.
PDE4 inhibitors described herein include, but are not limited to, known and studied PDE4 inhibitors such as theophylline, rolipram, roflumilast, cilomilast, aplet, ZL-n-91, and the like
Osteosarcomas described herein include various types of osteosarcomas of various characteristics, including, but not limited to, traditional osteosarcoma, intramedullary well-differentiated osteosarcoma, paraosteosarcoma, periosteal osteosarcoma, capillary-expanded osteosarcoma, and small cell osteosarcoma.
The formulation and specification of ZL-n-91 and chloroquine phosphate herein may be the same or different.
The ZL-n-91 and chloroquine phosphate in the application are preferably in an injection form, and can also be in an oral preparation form, and the specific preparation form can be an oral preparation form or an injection form, and comprises but is not limited to tablets, capsules, oral liquid preparations, pills, granules, powder, water injection, oil injection, emulsion injection, powder injection and the like.
In addition to oral or injectable dosage forms, other known or under-developed dosage forms such as transdermal administration, inhalation administration, targeted carrier administration, may be routinely selected and designed by those skilled in the pharmaceutical arts as appropriate.
In the treatment of osteosarcoma, ZL-n-91 may be used in combination with other known or developed agents for osteosarcoma treatment or formulated into the same formulation, including but not limited to chemotherapeutic agents and targeted agents.
The phosphodiesterase 4 inhibitor ZL-n-91 of the present invention can be purchased directly, synthesized by itself or by a person with reference to the existing literature, for example, ruihong Ma, bin-yan Yang, chang-you Wu. A selective phosphodiesterase 4 (PDE 4) inhibitor ZL-n-91 primers IL-17reduction by human memory 17 cells, international immunopharmacology,2008,8 (10): 1408-1417.
Has the advantages that: the selective PDE4 inhibitor ZL-n-91 can obviously inhibit the proliferation of tumor cells, and is expected to become an important target for anti-osteosarcoma proliferation research; meanwhile, chloroquine phosphate has the effect of inhibiting autophagy, can enhance the killing effect of ZL-n-91 on osteosarcoma cells, and has good application prospect on treatment of osteosarcoma.
Drawings
FIG. 1 is a graph showing the effect of ZL-n-91 in combination with CQ on the proliferation inhibition of osteosarcoma cells MNNG/HOS, saos-2, U2 OS: setting CQ concentration as 10 μ M, setting ZL-n-91 concentration as 200 μ M, treating the single drug group for 48h, pretreating the combined group with CQ for 2h, treating with ZL-n-91 for 48h, and detecting cell proliferation activity by viable cell counting method. All data are expressed as mean ± standard deviation. (n = 3), P <0.05, P <0.01, P <0.001.
FIG. 2 is a graph showing the effect of ZL-n-91 in combination with CQ on the interaction of MNNG/HOS, saos-2, U2OS osteosarcoma cells: the concentrations of CQ in single group were set to 0,2.5,5,10,20. Mu.M, that of ZL-n-91 in single group to 0,25,50,100,200. Mu.M, and the ratio of drug concentrations in combination group to 1 was set to 10, and 4 drug concentration groups were set, i.e., group one (2.5. Mu.M CQ + 25. Mu.M ZL-n-91), group two (5. Mu.M CQ + 50. Mu.M ZL-n-91), group three (10. Mu.M CQ + 100. Mu.M CQ-n-91), and group four (20. Mu.M CQ + 200. Mu.MZL-n-91), and the proliferation activities of various cells were determined by a viable cell count method, respectively by pre-treating MNNG/HOS, saos-2 and U2OS for 2h and then with ZL-n-91 for 48h. CalcuSyn software was used to analyze the CI values for CQ in combination with ZL-n-91. When the CI values are all less than 1, the synergistic effect is achieved, when the CI is equal to 1, the additive effect is achieved, and when the CI is greater than 1, the antagonistic effect is achieved.
FIG. 3 is a graph showing the effect of ZL-n-91 in combination with CQ on the proliferation inhibition of osteosarcoma cells MNNG/HOS, saos-2, U2 OS: cells in logarithmic growth phase are inoculated into a six-hole plate at proper concentration, and after the cells adhere to the wall, the drugs are added for treatment. Setting CQ concentration at 10 μ M, setting ZL-n-91 concentration at 200 μ M, treating the single drug group for 48h, pretreating the combined group with CQ for 2h, treating with ZL-n-91 for 48h, and changing fresh culture medium. The culture was terminated when macroscopic cell clones appeared, and the number of cell clones formed was counted by fixed staining observation. (n = 3), P <0.05, P <0.01, P <0.001.
FIG. 4 is a graph showing the pro-apoptotic effects of ZL-n-91 in combination with CQ on osteosarcoma cells MNNG/HOS, saos-2, U2 OS: setting CQ concentration as 10 μ M, setting ZL-n-91 concentration as 200 μ M, treating the single drug group for 48h, pretreating the combined group with CQ for 2h, treating with ZL-n-91 for 48h, and detecting apoptosis by flow cytometry. All data are expressed as mean ± standard deviation. (n = 3), P <0.05, P <0.01, P <0.001.
Detailed Description
In order to make the present invention more clear and intuitive for those skilled in the art, the present invention will be further described with reference to the accompanying drawings.
Example 1
Living cell counting method for detecting influence of combination of ZL-n-91 and CQ on osteosarcoma cell proliferation
1) Single cell suspensions were prepared from logarithmic phase cells U2OS, saos-2, MNNG/HOS. The cells were inoculated into six-well plates at 2ml per well, and divided into 4 groups: solvent control group (added with equal volume of solvent EtOH), CQ group (10. Mu.M), ZL-n-91 group (200. Mu.M), CQ + ZL-n-91 group, each group of 3 secondary wells;
2) After the cells adhere to the wall, adding CQ for pretreatment for 2 hours, and then adding ZL-n-91 for treatment for 48 hours;
3) After removing old medium, washing twice with PBS, cells were collected by trypsinization and counted.
The results are shown in FIG. 1: the CQ and ZL-n-91 can inhibit the proliferation of MNNG/HOS, U2OS and Saos-2 cells of osteosarcoma cells, and the cell activity of the combination of the CQ and the ZL-n-91 is further reduced.
Example 2
Calculation of CQ and ZL-n-91 combined action index
1) Single cell suspensions were prepared from cells in logarithmic growth phase U2OS, saos-2, MNNG/HOS. Inoculating 2ml of cell suspension per well into a six-well plate, setting 3 groups (CQ group alone, ZL-n-91 group alone, and CQ + ZL-n-91 group) for each cell, and 3 auxiliary wells for each group;
2) CQ working concentration is set to be 0,2.5,5,10 and 20 mu M, ZL-n-91 single group concentration is set to be 0,25,50,100 and 200 mu M, and the concentration ratio of the medicines in the combined group is 1.
3) After the cells adhere to the wall, the combined group is pretreated for 2 hours by CQ and then treated for 48 hours by ZL-n-91.
4) After removing old culture medium and washing with PBS twice, the cells are collected by trypsinization and counted to detect the cell viability. Data were entered into CalcuSyn software to calculate the Combination Index (CI). Wherein the CI value is less than 1, the synergistic effect is obtained, the additive effect is obtained when the CI value is equal to 1, and the antagonistic effect is obtained when the CI value is greater than 1.
The results are shown in FIG. 2: CQ has the capability of inhibiting osteosarcoma cell proliferation in cooperation with ZL-n-91
Experimental example 3
Plate clone formation experiment for detecting influence of ZL-n-91 and CQ on osteosarcoma cell clone formation capability
1) Single cell suspensions were prepared from cells in logarithmic growth phase U2OS, saos-2, MNNG/HOS. The cells were inoculated in six well plates at 2ml per well, and divided into 4 groups: solvent control group (added with equal volume of solvent EtOH), CQ group (10. Mu.M), ZL-n-91 group (200. Mu.M), CQ + ZL-n-91 group, each group of 3 secondary wells;
2) After the cells adhere to the wall, adding CQ for pretreatment for 2h, then adding ZL-n-91 for treatment for 48h, and replacing with fresh culture medium;
3) And (3) terminating the culture after 10 days of culture when macroscopic cell clones appear, fixing the cells by using a paraformaldehyde solution, carrying out crystal violet staining, washing by using PBS (phosphate buffer solution), marking more than or equal to 50 cell clone groups as 1 cell clone, observing and counting the formation number of each group of cell clones, and expressing the result by the formation number of the cell clones.
The results are shown in FIG. 3: CQ can remarkably enhance the inhibition effect of ZL-n-91 on the clonogenic capacity of osteosarcoma cells.
Experimental example 4
Flow cytometry detection of induction effect of combination of ZL-n-91 and CQ on osteosarcoma apoptosis
1) Single cell suspensions were prepared from logarithmic phase cells U2OS, saos-2, MNNG/HOS. The cells were inoculated in six well plates at 2ml per well, and divided into 4 groups: solvent control group (adding equal volume of solvent EtOH), CQ group (10. Mu.M), ZL-n-91 group (200. Mu.M), CQ + ZL-n-91 group, each group with 3 auxiliary holes;
2) After the cells adhere to the wall, adding CQ for pretreatment for 2 hours, and then adding ZL-n-91 for treatment for 48 hours;
3) After 48h cells were harvested, washed 2 times with cold PBS, 100. Mu.l of 1 BindingBuffer was added to prepare a cell suspension in a flow tube, 5. Mu.l of 7AA-D and 5. Mu.L of PE were added according to the kit instructions for staining, gently vortexed cells, incubated for 15min at room temperature in the dark, 200u1 BindingBuffer was added to the tube, flow cytometry was performed over 1h, and the results were analyzed by FlowJoV10 analytical software.
The results are shown in FIG. 4: CQ can remarkably enhance the apoptosis promoting effect mediated by ZL-n-91.
The research results show that the combined action of the phosphodiesterase 4 inhibitor ZL-n-91 and CQ can inhibit the cell proliferation of osteosarcoma, and the effect is superior to that of the single use of CQ and ZL-n-91, and the anti-tumor effect is good.
The embodiments described above are presented to enable those skilled in the art to make and use the invention. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the embodiments described herein, and those skilled in the art should make modifications and alterations to the present invention in light of the present disclosure.
Claims (19)
1. A combination for the treatment of a malignant tumour comprising a PDE4 inhibitor and chloroquine phosphate.
Use of a pde4 inhibitor and chloroquine phosphate in the preparation of a combination medicament for the treatment of malignant tumours.
3. The combination according to claim 1 or the use according to claim 2, wherein the malignancy is osteosarcoma.
4. The combination or use according to claim 3, wherein the malignant tumor is a traditional osteosarcoma, an intramedullary well-differentiated osteosarcoma, a paraosteosarcoma, an periosteal osteosarcoma, a capillary expanded osteosarcoma, a small cell osteosarcoma.
5. The combination according to claim 1 or the use according to claim 2, wherein the PDE4 inhibitor is selected from the group consisting of theophylline, rolipram, roflumilast, cilomilast, aplidine, ZL-n-91.
6. The combination or use according to claim 4, wherein the PDE4 inhibitor is ZL-n-91.
7. The combination according to claim 1 or the use according to claim 2, wherein the medicament inhibits tumor cell proliferation.
8. The combination as claimed in claim 1 or the use as claimed in claim 2, wherein the medicament induces apoptosis of tumour cells.
9. The combination according to claim 1 or the use according to claim 2, wherein the molar ratio of PDE4 inhibitor to chloroquine phosphate in the medicament is from 40.
10. The combination or use according to claim 9, wherein the molar ratio of PDE4 inhibitor to chloroquine phosphate in the medicament is 20.
11. The combination or use according to claim 10, wherein the molar ratio of PDE4 inhibitor to chloroquine phosphate in the medicament is 10.
12. The combination according to claim 1 or the use according to claim 2, wherein the PDE4 inhibitor and chloroquine phosphate in the medicament are administered simultaneously or separately.
13. A combination as claimed in claim 1 or use as claimed in claim 2, wherein the medicament is in an oral dosage form.
14. The combination or use according to claim 13, wherein the medicament is a tablet, capsule, oral liquid, pill, granule or powder.
15. The combination according to claim 1 or the use according to claim 2, wherein the medicament is in an injectable dosage form.
16. The drug combination or the application according to claim 15, wherein the drug is a liquid injection, an oil injection, a milk injection or a powder injection.
17. The combination according to claim 1 or the use according to claim 2, which is used in combination with or comprises a further agent for the treatment of osteosarcoma.
18. The combination or use according to claim 17, wherein the other osteosarcoma treating agent is a chemotherapeutic agent.
19. The combination or use according to claim 17, wherein the other osteosarcoma treating agent is a targeted agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110560718.6A CN115381954B (en) | 2021-05-21 | 2021-05-21 | Combined medicine for treating osteosarcoma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110560718.6A CN115381954B (en) | 2021-05-21 | 2021-05-21 | Combined medicine for treating osteosarcoma |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115381954A true CN115381954A (en) | 2022-11-25 |
CN115381954B CN115381954B (en) | 2023-12-05 |
Family
ID=84114379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110560718.6A Active CN115381954B (en) | 2021-05-21 | 2021-05-21 | Combined medicine for treating osteosarcoma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115381954B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110082148A1 (en) * | 2009-03-16 | 2011-04-07 | Gilles Klopman | Treating, preventing or ameliorating a hyperproliferative disease/disorder |
CN104257656A (en) * | 2014-10-23 | 2015-01-07 | 武汉大学 | Novel medicine composition for synergistically enhancing capacity of restraining tumor growth |
CN107714686A (en) * | 2016-08-10 | 2018-02-23 | 赵子建 | Applications of the phosphodiesterase 4 inhibitors ZL n 91 in treatment prostate cancer hyperplasia and diversion medicaments are prepared |
CN108186643A (en) * | 2018-04-09 | 2018-06-22 | 徐州维康生物科技有限公司 | It is a kind of that there is the pharmaceutical composition for cooperateing with anti-osteosarcoma effect and its application |
CN112220917A (en) * | 2020-10-16 | 2021-01-15 | 广东工业大学 | Combined medicine for treating malignant tumor |
-
2021
- 2021-05-21 CN CN202110560718.6A patent/CN115381954B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110082148A1 (en) * | 2009-03-16 | 2011-04-07 | Gilles Klopman | Treating, preventing or ameliorating a hyperproliferative disease/disorder |
CN104257656A (en) * | 2014-10-23 | 2015-01-07 | 武汉大学 | Novel medicine composition for synergistically enhancing capacity of restraining tumor growth |
CN107714686A (en) * | 2016-08-10 | 2018-02-23 | 赵子建 | Applications of the phosphodiesterase 4 inhibitors ZL n 91 in treatment prostate cancer hyperplasia and diversion medicaments are prepared |
CN108186643A (en) * | 2018-04-09 | 2018-06-22 | 徐州维康生物科技有限公司 | It is a kind of that there is the pharmaceutical composition for cooperateing with anti-osteosarcoma effect and its application |
CN112220917A (en) * | 2020-10-16 | 2021-01-15 | 广东工业大学 | Combined medicine for treating malignant tumor |
Non-Patent Citations (1)
Title |
---|
刘卫东 等: "雷帕霉素与自噬抑制剂氯奎抗骨肉瘤的联合作用", 《中华医学杂志》, vol. 97, no. 19, pages 1510 - 1514 * |
Also Published As
Publication number | Publication date |
---|---|
CN115381954B (en) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08502488A (en) | Tumoricidal activity of benzoquinoid ansamycin against prostate cancer and early neurological malignancies | |
CN110522753A (en) | A kind of new type antineoplastic medicine composition, preparation and application | |
JP4944380B2 (en) | Extracts with antitumor and antitoxic activity | |
CN105476996A (en) | Application of curcumin and afatinib for combined treatment of non-small cell lung cancer | |
ZA200305967B (en) | Method of cancer therapy | |
US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
MXPA06014477A (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer. | |
CN102526731B (en) | Pharmaceutical composition containing arctigenin | |
TW202034919A (en) | Use of chiauranib in treating small cell lung cancer | |
CN115381954B (en) | Combined medicine for treating osteosarcoma | |
EP2768498B1 (en) | Therapeutic combination for the treatment of cancer | |
CN113274394B (en) | Pharmaceutical composition for treating tyrosine kinase inhibitor drug-resistant non-small cell lung cancer | |
AU2020255063B2 (en) | Combined use of A-nor-5α androstane compound drug and anticancer drug | |
WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
CA2557857C (en) | Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation | |
MX2010009502A (en) | Combination anti-cancer agents. | |
CN115721722A (en) | Pharmaceutical composition for treating EGFR-TKI-resistant non-small cell lung cancer | |
CN111939165B (en) | Application of non-natural ginsenoside 3 beta-O-Glc-DM in preparation of medicine for preventing or treating glioblastoma | |
CN105343095A (en) | Application of regorafenib and lapatinib in preparation of antitumor combination drug | |
Weinberg et al. | PP01. 55 Patient-reported experience as a baseline for 4R care sequence implementation at 9 cancer centers | |
CN117357533A (en) | Application of combination of obutylamine fumarate and temozolomide in treating brain glioma | |
CN103948627B (en) | For treating the pharmaceutical composition of small cell carcinoma | |
CN116585479A (en) | Treatment of non-small cell lung cancer by combining Sidamide with tirelimumab and chemotherapeutic drugs | |
CN115779040A (en) | Traditional Chinese medicine composition for improving treatment effect of immune checkpoint inhibitor and application thereof | |
CN115381958A (en) | Application of eIF4E inhibitor and PARP inhibitor drug combination in preparation of drugs for treating lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230925 Address after: 518118 Room 201, building 2, Huahan science and Technology Industrial Park, No. 19, Qiyun West Road, Heping community, Pingshan street, Pingshan District, Shenzhen, Guangdong Applicant after: Shenzhen Hanhui Pharmaceutical Technology Co.,Ltd. Address before: No. 3, Kexue Road, Science City, Guangzhou Hi tech Development Zone, 510000 Guangdong Province Applicant before: GUANGZHOU HUAZHEN PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |